AIM
TBIO

Advantage Investment Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Advantage Investment Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$10K – 978
2019
Q1 		$10K Buy
+1,000
New +$7.67K 0.01% 653

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Advantage Investment Management's TBIO Position: Q2 2019 in Review

Advantage Investment Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2019, closing a stake of 1,000 shares — an estimated $10K sold.

Advantage Investment Management first reported a position in TBIO in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 60 funds tracked by Wall St. Rank hold TBIO as of Q2 2019.

  • Advantage Investment Management reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Advantage Investment Management sold 1,000 Translate Bio, Inc. Common Stock shares in Q2 2019, an estimated $10K.
  • Advantage Investment Management first reported a position in Translate Bio, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Advantage Investment Management's Translate Bio, Inc. Common Stock position peaked at $10K in Q1 2019.
  • 60 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2019.

Based on Advantage Investment Management's 13F filing for Q2 2019, filed 30 Jul 2019.